{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T17:03:20Z","timestamp":1776791000679,"version":"3.51.2"},"reference-count":132,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2021,5,25]],"date-time":"2021-05-25T00:00:00Z","timestamp":1621900800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["CEECIND\/00630\/2017"],"award-info":[{"award-number":["CEECIND\/00630\/2017"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["SFRH\/BD\/135915\/2018"],"award-info":[{"award-number":["SFRH\/BD\/135915\/2018"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["PTDC\/QUI-QIN\/0146\/2020"],"award-info":[{"award-number":["PTDC\/QUI-QIN\/0146\/2020"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["UIDB\/00100\/2020"],"award-info":[{"award-number":["UIDB\/00100\/2020"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["UID\/Multi\/04349\/2020"],"award-info":[{"award-number":["UID\/Multi\/04349\/2020"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>Cisplatin and derivatives are highly effective in the treatment of a wide range of cancer types; however, these metallodrugs display low selectivity, leading to severe side effects. Additionally, their administration often results in the development of chemoresistance, which ultimately results in therapeutic failure. This scenario triggered the study of other transition metals with innovative pharmacological profiles as alternatives to platinum, ruthenium- (e.g., KP1339 and NAMI-A) and gold-based (e.g., Auranofin) complexes being among the most advanced in terms of clinical evaluation. Concerning the importance of improving the in vivo selectivity of metal complexes and the current relevance of ruthenium and gold metals, this review article aims to survey the main research efforts made in the past few years toward the design and biological evaluation of target-specific ruthenium and gold complexes. Herein, we give an overview of the inorganic and organometallic molecules conjugated to different biomolecules for targeting membrane proteins, namely cell adhesion molecules, G-protein coupled receptors, and growth factor receptors. Complexes that recognize the progesterone receptors or other targets involved in metabolic pathways such as glucose transporters are discussed as well. Finally, we describe some complexes aimed at recognizing cell organelles or compartments, mitochondria being the most explored. The few complexes addressing targeted gene therapy are also presented and discussed.<\/jats:p>","DOI":"10.3390\/molecules26113153","type":"journal-article","created":{"date-parts":[[2021,5,25]],"date-time":"2021-05-25T13:14:21Z","timestamp":1621948461000},"page":"3153","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Emerging Molecular Receptors for the Specific-Target Delivery of Ruthenium and Gold Complexes into Cancer Cells"],"prefix":"10.3390","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3741-2386","authenticated-orcid":false,"given":"Jo\u00e3o Franco","family":"Machado","sequence":"first","affiliation":[{"name":"Centro de Qu\u00edmica Estrutural and Departamento de Qu\u00edmica e Bioqu\u00edmica, Faculdade de Ci\u00eancias, Universidade de Lisboa, Campo Grande, 1749-016 Lisbon, Portugal"},{"name":"Centro de Ci\u00eancias e Tecnologias Nucleares and Departamento de Engenharia e Ci\u00eancias Nucleares, Instituto Superior T\u00e9cnico, Universidade de Lisboa, Estrada Nacional 10 (km 139, 7), 2695-066 Bobadela LRS, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7847-4906","authenticated-orcid":false,"given":"Jo\u00e3o D. G.","family":"Correia","sequence":"additional","affiliation":[{"name":"Centro de Ci\u00eancias e Tecnologias Nucleares and Departamento de Engenharia e Ci\u00eancias Nucleares, Instituto Superior T\u00e9cnico, Universidade de Lisboa, Estrada Nacional 10 (km 139, 7), 2695-066 Bobadela LRS, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0233-8243","authenticated-orcid":false,"given":"T\u00e2nia S.","family":"Morais","sequence":"additional","affiliation":[{"name":"Centro de Qu\u00edmica Estrutural and Departamento de Qu\u00edmica e Bioqu\u00edmica, Faculdade de Ci\u00eancias, Universidade de Lisboa, Campo Grande, 1749-016 Lisbon, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2021,5,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"12888","DOI":"10.1039\/D0SC04082G","article-title":"Metallodrugs are unique: Opportunities and challenges of discovery and development","volume":"11","author":"Anthony","year":"2020","journal-title":"Chem. Sci."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1021\/acs.chemrev.8b00396","article-title":"Metal drugs and the anticancer immune response","volume":"119","author":"Englinger","year":"2019","journal-title":"Chem. Rev."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"4209","DOI":"10.1039\/C3DT52524D","article-title":"A golden future in medicinal inorganic chemistry: The promise of anticancer gold organometallic compounds","volume":"43","author":"Bertrand","year":"2014","journal-title":"Dalt. Trans."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"5950","DOI":"10.1039\/C4DT00022F","article-title":"Gold complexes as antimicrobial agents: An overview of different biological activities in relation to the oxidation state of the gold ion and the ligand structure","volume":"43","author":"Djuran","year":"2014","journal-title":"J. Chem. Soc. Dalt. Trans."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"8786","DOI":"10.1039\/C5CS00132C","article-title":"Chemical biology of anticancer gold(III) and gold(i) complexes","volume":"44","author":"Zou","year":"2015","journal-title":"Chem. Soc. Rev."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1210\/er.2002-0007","article-title":"Peptide receptors as molecular targets for cancer diagnosis and therapy","volume":"24","author":"Reubi","year":"2003","journal-title":"Endocr. Rev."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3470","DOI":"10.1158\/1078-0432.CCR-07-0264","article-title":"Nuclear imaging probes: From bench to bedside","volume":"13","author":"Wester","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.ymeth.2009.03.012","article-title":"Molecular imaging targeting peptide receptors","volume":"48","author":"Schottelius","year":"2009","journal-title":"Methods"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1021\/ar800215p","article-title":"Peptide-Targeted Diagnostics and Radiotherapeutics","volume":"42","author":"Tweedle","year":"2009","journal-title":"Acc. Chem. Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.2967\/jnumed.108.053041","article-title":"Peptide-based probes for cancer imaging","volume":"49","author":"Reubi","year":"2008","journal-title":"J. Nucl. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"8452","DOI":"10.1039\/C4TB01263A","article-title":"Biomolecules-conjugated nanomaterials for targeted cancer therapy","volume":"2","author":"Wang","year":"2014","journal-title":"J. Mater. Chem. B"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/PPO.0000000000000104","article-title":"Alternative fuels for cancer cells","volume":"21","author":"Keenan","year":"2015","journal-title":"J. Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jons.2017.06.002","article-title":"Biology of glucose metabolization in cancer cells","volume":"3","author":"Fadaka","year":"2017","journal-title":"J. Oncol. Sci."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"815","DOI":"10.2174\/1389200220666191003161114","article-title":"Recognition Sites for Cancer-targeting Drug Delivery Systems","volume":"20","author":"Guan","year":"2019","journal-title":"Curr. Drug Metab."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12929-019-0592-z","article-title":"Development of therapeutic antibodies for the treatment of diseases","volume":"27","author":"Lu","year":"2020","journal-title":"J. Biomed. Sci."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/s13238-017-0457-8","article-title":"Current progress in innovative engineered antibodies","volume":"9","author":"Strohl","year":"2018","journal-title":"Protein Cell"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1021\/acs.bioconjchem.0c00617","article-title":"Radiolabeled Peptides and Antibodies in Medicine","volume":"32","author":"Czarnecka","year":"2021","journal-title":"Bioconjug. Chem."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ejmech.2019.06.014","article-title":"Biomedical applications of radioiodinated peptides","volume":"179","author":"Oliveira","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"6144","DOI":"10.1039\/c0dt01599g","article-title":"Radiometallated peptides for molecular imaging and targeted therapy","volume":"40","author":"Correia","year":"2011","journal-title":"Dalt. Trans."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"527","DOI":"10.4155\/fmc.16.7","article-title":"Tracking antitumor metallodrugs: Promising agents with the Ru(II)- and Fe(II)-cyclopentadienyl scaffolds","volume":"8","author":"Morais","year":"2016","journal-title":"Future Med. Chem."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1080\/00958972.2017.1349313","article-title":"Review: Recent advances and future development of metal complexes as anticancer agents","volume":"70","author":"Jia","year":"2017","journal-title":"J. Coord. Chem."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"777","DOI":"10.2174\/138161209787582183","article-title":"Metal Complexes, their Cellular Targets and Potential for Cancer Therapy","volume":"15","author":"Chen","year":"2009","journal-title":"Curr. Pharm. Des."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.2174\/138161210791209009","article-title":"Novel Metals and Metal Complexes as Platforms for Cancer Therapy","volume":"16","author":"Frezza","year":"2010","journal-title":"Curr. Pharm. Des."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"599","DOI":"10.2147\/DDDT.S119488","article-title":"Metal complexes in cancer therapy\u2014An update from drug design perspective","volume":"11","author":"Ndagi","year":"2017","journal-title":"Drug Des. Devel. Ther."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.ccr.2016.09.004","article-title":"Update on metal N-heterocyclic carbene complexes as potential anti-tumor metallodrugs","volume":"329","author":"Liu","year":"2016","journal-title":"Coord. Chem. Rev."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1021\/acs.chemrev.8b00211","article-title":"Transition Metal Complexes and Photodynamic Therapy from a Tumor-Centered Approach: Challenges, Opportunities, and Highlights from the Development of TLD1433","volume":"119","author":"Monro","year":"2019","journal-title":"Chem. Rev."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Sudhindra, P., Ajay Sharma, S., Roy, N., Moharana, P., and Paira, P. (2020). Recent advances in cytotoxicity, cellular uptake and mechanism of action of ruthenium metallodrugs: A review. Polyhedron, 192.","DOI":"10.1016\/j.poly.2020.114827"},{"key":"ref_28","first-page":"303","article-title":"Non-covalent metallo-drugs: Using shape to target DNA and RNA junctions and other nucleic acid structures","volume":"18","author":"Cardo","year":"2018","journal-title":"Metallo-Drugs: Development and Action of Anticancer Agents"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s10637-014-0179-1","article-title":"Phase I\/II study with ruthenium compound NAMI-A and gemcitabine in patients with non-small cell lung cancer after first line therapy","volume":"33","author":"Leijen","year":"2015","journal-title":"Invest. New Drugs"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Burris, H.A., Bakewell, S., Bendell, J.C., Infante, J., Jones, S.F., Spigel, D.R., Weiss, G.J., Ramanathan, R.K., Ogden, A., and Von Hoff, D. (2016). Safety and activity of IT-139, a ruthenium-based compound, in patients with advanced solid tumours: A first-in-human, open-label, dose-escalation phase i study with expansion cohort. ESMO Open, 1.","DOI":"10.1136\/esmoopen-2016-000154"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Alessio, E., and Messori, L. (2019). NAMI-A and KP1019\/1339, Two Iconic Ruthenium Anticancer Drug Candidates Face-to-Face: A Case Story in Medicinal Inorganic Chemistry. Molecules, 24.","DOI":"10.3390\/molecules24101995"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1089\/ars.2010.3663","article-title":"Anticancer activity of metal complexes: Involvement of redox processes","volume":"15","author":"Jungwirth","year":"2011","journal-title":"Antioxid. Redox Signal."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1039\/C7CS00332C","article-title":"Structure-activity relationships for ruthenium and osmium anticancer agents-towards clinical development","volume":"47","author":"Gerner","year":"2018","journal-title":"Chem. Soc. Rev."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jorganchem.2018.04.023","article-title":"Medicinal Applications of Gold(I\/III)-Based Complexes Bearing N-Heterocyclic Carbene and Phosphine Ligands","volume":"866","author":"Dominelli","year":"2018","journal-title":"J. Organomet. Chem."},{"key":"ref_35","unstructured":"(2021, May 03). Home\u2014ClinicalTrials.gov, Available online: https:\/\/www.clinicaltrials.gov\/."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Harjunp\u00e4\u00e4, H., Asens, M.L., Guenther, C., and Fagerholm, S.C. (2019). Cell adhesion molecules and their roles and regulation in the immune and tumor microenvironment. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.01078"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1002\/jps.20676","article-title":"Cell Adhesion Molecules for Targeted Drug Delivery","volume":"95","author":"Dunehoo","year":"2006","journal-title":"J. Pharm. Sci."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/nrm2871","article-title":"The final steps of integrin activation: The end game","volume":"11","author":"Shattil","year":"2010","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1152\/physrev.00036.2018","article-title":"Cell adhesion by integrins","volume":"99","author":"Bachmann","year":"2019","journal-title":"Physiol. Rev."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.ccell.2019.01.007","article-title":"Integrin Signaling in Cancer: Mechanotransduction, Stemness, Epithelial Plasticity, and Therapeutic Resistance","volume":"35","author":"Cooper","year":"2019","journal-title":"Cancer Cell"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"154","DOI":"10.7150\/thno\/v01p0154","article-title":"Integrin Targeted Therapeutics","volume":"1","author":"Millard","year":"2012","journal-title":"Theranostics"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.trecan.2018.05.009","article-title":"Glycosylation and Integrin Regulation in Cancer","volume":"4","author":"Marsico","year":"2018","journal-title":"Trends Cancer"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.drup.2005.10.002","article-title":"RGD-based strategies for selective delivery of therapeutics and imaging agents to the tumour vasculature","volume":"8","author":"Temming","year":"2005","journal-title":"Drug Resist. Updat."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"579","DOI":"10.4155\/fmc-2017-0008","article-title":"RGD-mediated delivery of small-molecule drugs","volume":"9","author":"Katsamakas","year":"2017","journal-title":"Future Med. Chem."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"14098","DOI":"10.1021\/ja205235m","article-title":"Photocontrolled DNA binding of a receptor-targeted organometallic ruthenium(II) complex","volume":"133","author":"Salassa","year":"2011","journal-title":"J. Am. Chem. Soc."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1002\/ejic.201601094","article-title":"Functionalization of Ruthenium(II) Terpyridine Complexes with Cyclic RGD Peptides To Target Integrin Receptors in Cancer Cells","volume":"2017","author":"Hahn","year":"2017","journal-title":"Eur. J. Inorg. Chem."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Hu, J.J., Lei, Q., and Zhang, X.Z. (2020). Recent advances in photonanomedicines for enhanced cancer photodynamic therapy. Prog. Mater. Sci., 114.","DOI":"10.1016\/j.pmatsci.2020.100685"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"12542","DOI":"10.1039\/D0CC04943C","article-title":"Two-photon photodynamic ablation of tumour cells using an RGD peptide-conjugated ruthenium(ii) photosensitiser","volume":"56","author":"Zhao","year":"2020","journal-title":"Chem. Commun."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.ajps.2019.08.003","article-title":"Tumor microenvironment responsive drug delivery systems","volume":"15","author":"He","year":"2020","journal-title":"Asian J. Pharm. Sci."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.biomaterials.2018.12.002","article-title":"Designing luminescent ruthenium prodrug for precise cancer therapy and rapid clinical diagnosis","volume":"192","author":"Zhao","year":"2019","journal-title":"Biomaterials"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"5941","DOI":"10.1039\/D0CC00774A","article-title":"Targeted imaging of integrins in cancer tissues using photocleavable Ru(ii) polypyridine complexes as mass-tags","volume":"56","author":"Han","year":"2020","journal-title":"Chem. Commun."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"4572","DOI":"10.1021\/acs.molpharmaceut.9b00695","article-title":"Bioconjugation of Cyclometalated Gold(III) Lipoic Acid Fragments to Linear and Cyclic Breast Cancer Targeting Peptides","volume":"16","author":"Slootweg","year":"2019","journal-title":"Mol. Pharm."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Gloushankova, N.A., Rubtsova, S.N., and Zhitnyak, I.Y. (2017). Cadherin-mediated cell-cell interactions in normal and cancer cells. Tissue Barriers, 5.","DOI":"10.1080\/21688370.2017.1356900"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.critrevonc.2017.11.010","article-title":"E-cadherin: Its dysregulation in carcinogenesis and clinical implications","volume":"121","author":"Wong","year":"2018","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Blaschuk, O.W. (2015). N-cadherin antagonists as oncology therapeutics. Philos. Trans. R. Soc. B Biol. Sci., 370.","DOI":"10.1098\/rstb.2014.0039"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1021\/mp400624v","article-title":"Modulation of blood-brain barrier permeability in mice using synthetic E-cadherin peptide","volume":"11","author":"On","year":"2014","journal-title":"Mol. Pharm."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jinorgbio.2016.02.011","article-title":"Synthesis, characterization and biological evaluation of a 67Ga-labeled (\u03b76-Tyr)Ru(\u03b75-Cp) peptide complex with the HAV motif","volume":"160","author":"Bihari","year":"2016","journal-title":"J. Inorg. Biochem."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1021\/acs.chemrev.6b00177","article-title":"GPCR dynamics: Structures in motion","volume":"117","author":"Latorraca","year":"2017","journal-title":"Chem. Rev."},{"key":"ref_59","first-page":"1","article-title":"G protein-coupled receptors: Structure- and function-based drug discovery","volume":"6","author":"Yang","year":"2021","journal-title":"Signal. Transduct. Target. Ther."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/nrd.2017.178","article-title":"Trends in GPCR drug discovery: New agents, targets and indications","volume":"16","author":"Hauser","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Franco Machado, J., Silva, R., Melo, R.G., and Correia, J. (2018). Less Exploited GPCRs in Precision Medicine: Targets for Molecular Imaging and Theranostics. Molecules, 24.","DOI":"10.3390\/molecules24010049"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"345","DOI":"10.3389\/fendo.2018.00345","article-title":"Neuropeptide G protein-coupled receptors as oncotargets","volume":"9","author":"Moody","year":"2018","journal-title":"Front. Endocrinol. (Lausanne)."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2","DOI":"10.2174\/156720111793663633","article-title":"Somatostatin Receptor-Targeted Anti-Cancer Therapy","volume":"8","author":"Sun","year":"2011","journal-title":"Curr. Drug Deliv."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"12552","DOI":"10.1039\/C5CC03473F","article-title":"Receptor selective ruthenium-somatostatin photosensitizer for cancer targeted photodynamic applications","volume":"51","author":"Wang","year":"2015","journal-title":"Chem. Commun."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-019-57172-6","article-title":"Somatostatin receptor mediated targeting of acute myeloid leukemia by photodynamic metal complexes for light induced apoptosis","volume":"10","author":"Vegi","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1021\/bc300173h","article-title":"Somatostatin subtype-2 receptor-targeted metal-based anticancer complexes","volume":"23","author":"Sadler","year":"2012","journal-title":"Bioconjug. Chem."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1517\/14728222.2016.1164694","article-title":"Bombesin related peptides\/receptors and their promising therapeutic roles in cancer imaging, targeting and treatment","volume":"20","author":"Moreno","year":"2016","journal-title":"Expert Opin. Ther. Targets"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1002\/cmdc.201400029","article-title":"Bis(dipyridophenazine)(2-(2\u2032-pyridyl)pyrimidine-4-carboxylic acid)ruthenium(II) Hexafluorophosphate: A Lesson in Stubbornness","volume":"9","author":"Joshi","year":"2014","journal-title":"ChemMedChem"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"4874","DOI":"10.1039\/C4DT02977A","article-title":"Towards the elaboration of new gold-based optical theranostics","volume":"44","author":"Doulain","year":"2015","journal-title":"Dalt. Trans."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1146\/annurev.biochem.73.011303.073940","article-title":"Opioid Receptors","volume":"73","author":"Waldhoer","year":"2004","journal-title":"Annu. Rev. Biochem."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s11864-019-0699-1","article-title":"Opioids in Cancer Development, Progression and Metastasis: Focus on Colorectal Cancer","volume":"21","author":"Szczepaniak","year":"2020","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"9297","DOI":"10.1002\/chem.201300889","article-title":"Identification of the Structural Determinants for Anticancer Activity of a Ruthenium Arene Peptide Conjugate","volume":"19","author":"Meier","year":"2013","journal-title":"Chem. Eur. J."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"12158","DOI":"10.1002\/chem.202002067","article-title":"Luminescent Bimetallic Ir III \/Au I Peptide Bioconjugates as Potential Theranostic Agents","volume":"26","author":"Luengo","year":"2020","journal-title":"Chem. Eur. J."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jsbmb.2017.03.021","article-title":"Twenty years of the G protein-coupled estrogen receptor GPER: Historical and personal perspectives","volume":"176","author":"Barton","year":"2018","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pharmthera.2017.12.012","article-title":"Selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs) in cancer treatment","volume":"186","author":"Patel","year":"2018","journal-title":"Pharmacol. Ther."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Hsu, L.-H., Chu, N.-M., Lin, Y.-F., and Kao, S.-H. (2019). G-Protein Coupled Estrogen Receptor in Breast Cancer. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20020306"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"3613","DOI":"10.1002\/chem.201705902","article-title":"A Gold(III) Pincer Ligand Scaffold for the Synthesis of Binuclear and Bioconjugated Complexes: Synthesis and Anticancer Potential","volume":"24","author":"Bertrand","year":"2018","journal-title":"Chem. Eur. J."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"7038","DOI":"10.1039\/C8CC03786H","article-title":"An estrogen receptor targeted ruthenium complex as a two-photon photodynamic therapy agent for breast cancer cells","volume":"54","author":"Zhao","year":"2018","journal-title":"Chem. Commun."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1021\/acs.organomet.8b00897","article-title":"Organoruthenium(II) Complexes Bearing an Aromatase Inhibitor: Synthesis, Characterization, in Vitro Biological Activity and in Vivo Toxicity in Zebrafish Embryos","volume":"38","author":"Golbaghi","year":"2019","journal-title":"Organometallics"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1152\/physiol.00045.2009","article-title":"Roles for Growth Factors in Cancer Progression","volume":"25","author":"Witsch","year":"2010","journal-title":"Physiology"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1056\/NEJMra044389","article-title":"Tyrosine Kinases as Targets for Cancer Therapy","volume":"353","author":"Krause","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"50209","DOI":"10.18632\/oncotarget.16854","article-title":"Epidermal growth factor receptor (EGFR): A rising star in the era of precision medicine of lung cancer","volume":"8","author":"Liu","year":"2017","journal-title":"Oncotarget"},{"key":"ref_83","first-page":"967","article-title":"Epidermal Growth Factor Receptor: Key to Selective Intracellular Delivery","volume":"85","author":"Rosenkranz","year":"2020","journal-title":"Biochem."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1016\/j.ejmech.2010.01.040","article-title":"(Arene)Ru(II) complexes of epidermal growth factor receptor inhibiting tyrphostins with enhanced selectivity and cytotoxicity in cancer cells","volume":"45","author":"Biersack","year":"2010","journal-title":"Eur. J. Med. Chem."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"10224","DOI":"10.1039\/c3cc43000f","article-title":"Complexation with organometallic ruthenium pharmacophores enhances the ability of 4-anilinoquinazolines inducing apoptosis","volume":"49","author":"Zheng","year":"2013","journal-title":"Chem. Commun."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"13100","DOI":"10.1039\/C5DT01430A","article-title":"Dual-targeting organometallic ruthenium(ii) anticancer complexes bearing EGFR-inhibiting 4-anilinoquinazoline ligands","volume":"44","author":"Zhang","year":"2015","journal-title":"Dalt. Trans."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1039\/C5MT00122F","article-title":"Discovery of a dual-targeting organometallic ruthenium complex with high activity inducing early stage apoptosis of cancer cells","volume":"7","author":"Du","year":"2015","journal-title":"Metallomics"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"4260","DOI":"10.1021\/acs.molpharmaceut.9b00608","article-title":"A Novel Conjugate of Bis[((4-bromophenyl)amino)quinazoline], a EGFR-TK Ligand, with a Fluorescent Ru(II)-Bipyridine Complex Exhibits Specific Subcellular Localization in Mitochondria","volume":"16","author":"Ilmi","year":"2019","journal-title":"Mol. Pharm."},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Ortega, E., Zamora, A., Basu, U., Lippmann, P., Rodr\u00edguez, V., Janiak, C., Ott, I., and Ruiz, J. (2020). An Erlotinib gold(I) conjugate for combating triple-negative breast cancer. J. Inorg. Biochem., 203.","DOI":"10.1016\/j.jinorgbio.2019.110910"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s41571-019-0268-3","article-title":"HER2-targeted therapies\u2014a role beyond breast cancer","volume":"17","author":"Oh","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1039\/C8CC08769E","article-title":"Trastuzumab gold-conjugates: Synthetic approach and: In vitro evaluation of anticancer activities in breast cancer cell lines","volume":"55","author":"Curado","year":"2019","journal-title":"Chem. Commun."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"16052","DOI":"10.18632\/oncotarget.14109","article-title":"Inhibition of the fibroblast growth factor receptor (FGFR) pathway: The current landscape and barriers to clinical application","volume":"8","author":"Chae","year":"2017","journal-title":"Oncotarget"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.critrevonc.2017.02.018","article-title":"FGFR a promising druggable target in cancer: Molecular biology and new drugs","volume":"113","author":"Porta","year":"2017","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.breast.2017.10.014","article-title":"Targeting FGFR pathway in breast cancer","volume":"37","author":"Soberino","year":"2018","journal-title":"Breast"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"5974","DOI":"10.1039\/D0DT00955E","article-title":"Novel \u201cruthenium cyclopentadienyl\u201d\u2014peptide conjugate complexes against human FGFR(+) breast cancer","volume":"49","author":"Machuqueiro","year":"2020","journal-title":"Dalt. Trans."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"9164","DOI":"10.1021\/ic201388n","article-title":"A potent ruthenium(II) antitumor complex bearing a lipophilic levonorgestrel group","volume":"50","author":"Ruiz","year":"2011","journal-title":"Inorg. Chem."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"3419","DOI":"10.1039\/C8NJ04159H","article-title":"Enhancement of therapeutic effect in breast cancer with a steroid-conjugated ruthenium complex","volume":"43","author":"Lv","year":"2019","journal-title":"New, J. Chem."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"7706","DOI":"10.1039\/C7CS00680B","article-title":"The development of ruthenium(II) polypyridyl complexes and conjugates for: In vitro cellular and in vivo applications","volume":"46","author":"Poynton","year":"2017","journal-title":"Chem. Soc. Rev."},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Flamme, M., Clarke, E., Gasser, G., and Hollenstein, M. (2018). Applications of Ruthenium Complexes Covalently Linked to Nucleic Acid Derivatives. Molecules, 23.","DOI":"10.3390\/molecules23071515"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"9904","DOI":"10.1039\/C9CC04098F","article-title":"Functionalization and cancer-targeting design of ruthenium complexes for precise cancer therapy","volume":"55","author":"Liu","year":"2019","journal-title":"Chem. Commun."},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Yeo, C., Ooi, K., and Tiekink, E. (2018). Gold-Based Medicine: A Paradigm Shift in Anti-Cancer Therapy?. Molecules, 23.","DOI":"10.3390\/molecules23061410"},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Andrejevi\u0107, T.P., Gli\u0161i\u0107, B.\u0110., and Djuran, M.I. (2020). Amino Acids and Peptides as Versatile Ligands in the Synthesis of Antiproliferative Gold Complexes. Chemistry, 2.","DOI":"10.3390\/chemistry2020013"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"3831","DOI":"10.1016\/j.jmb.2016.06.020","article-title":"Progesterone Receptor Signaling Mechanisms","volume":"428","author":"Grimm","year":"2016","journal-title":"J. Mol. Biol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1586\/eem.11.25","article-title":"Progesterone receptor action: Defining a role in breast cancer","volume":"6","author":"Daniel","year":"2011","journal-title":"Expert Rev. Endocrinol. Metab."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.mce.2016.06.027","article-title":"Membrane progesterone receptors in reproduction and cancer","volume":"434","year":"2016","journal-title":"Mol. Cell. Endocrinol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"5465","DOI":"10.1021\/ol0620646","article-title":"Ruthenium half-sandwich complexes as protein kinase inhibitors: An N-succinimidyl ester for rapid derivatizations of the cyclopentadienyl moiety","volume":"8","author":"Bregman","year":"2006","journal-title":"Org. Lett."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.poly.2014.07.024","article-title":"Structural features and cytotoxic activities of [Ru(AA-H)(dppb)(bipy)] PF6 complexes","volume":"81","author":"Almeida","year":"2014","journal-title":"Polyhedron"},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Lima, A.P., Pereira, F.C., Almeida, M.A.P., Mello, F.M.S., Pires, W.C., Pinto, T.M., Delella, F.K., Felisbino, S.L., Moreno, V., and Batista, A.A. (2014). Cytoxicity and Apoptotic Mechanism of Ruthenium(II) Amino Acid Complexes in Sarcoma-180 Tumor Cells. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0105865"},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"de Sousa, I.H., Campos, V.N.S., Vale, A.A.M., Maciel-Silva, V.L., Leite, C.M., Lopes, A.J.O., Mour\u00e3o, P.S., das Chagas Alves Lima, F., Batista, A.A., and de Azevedo dos Santos, A.P.S. (2020). Ruthenium (II) complexes with N, O-chelating proline and threonine ligands cause selective cytotoxicity by the induction of genomic instability, cell cycle arrest and apoptosis in breast and prostate tumor cells. Toxicol. Vitr., 62.","DOI":"10.1016\/j.tiv.2019.104679"},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Nardon, C., Schmitt, S.M., Yang, H., Zuo, J., Fregona, D., and Dou, Q.P. (2014). Gold(III)-Dithiocarbamato Peptidomimetics in the Forefront of the Targeted Anticancer Therapy: Preclinical Studies against Human Breast Neoplasia. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0084248"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1002\/cmdc.201800098","article-title":"Anticancer Gold(III) Peptidomimetics: From Synthesis to in vitro and ex vivo Biological Evaluations","volume":"13","author":"Boscutti","year":"2018","journal-title":"ChemMedChem"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1002\/cmdc.201900226","article-title":"Cu II and Au III Complexes with Glycoconjugated Dithiocarbamato Ligands for Potential Applications in Targeted Chemotherapy","volume":"14","author":"Pettenuzzo","year":"2019","journal-title":"ChemMedChem"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"5839","DOI":"10.1039\/D0CC01148G","article-title":"Boosting two-photon photodynamic therapy with mitochondria-targeting ruthenium-glucose conjugates","volume":"56","author":"Liu","year":"2020","journal-title":"Chem. Commun."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"10972","DOI":"10.1039\/C9CC05826E","article-title":"A biotinylated ruthenium(ii) photosensitizer for tumor-targeted two-photon photodynamic therapy","volume":"55","author":"Li","year":"2019","journal-title":"Chem. Commun."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.ejmech.2018.12.022","article-title":"Unprecedented inhibition of P-gp activity by a novel ruthenium-cyclopentadienyl compound bearing a bipyridine-biotin ligand","volume":"163","author":"Karas","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"9135","DOI":"10.1021\/acs.inorgchem.9b00735","article-title":"Ruthenium-Cyclopentadienyl Bipyridine-Biotin Based Compounds: Synthesis and Biological Effect","volume":"58","author":"Karas","year":"2019","journal-title":"Inorg. Chem."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1021\/acs.inorgchem.9b03178","article-title":"Ruthenium(II) Conjugates of Boron-Dipyrromethene and Biotin for Targeted Photodynamic Therapy in Red Light","volume":"59","author":"Paul","year":"2020","journal-title":"Inorg. Chem."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.1002\/chem.201705561","article-title":"Cancer-Targeting Functionalization of Selenium-Containing Ruthenium Conjugate with Tumor Microenvironment-Responsive Property to Enhance Theranostic Effects","volume":"24","author":"Zhao","year":"2018","journal-title":"Chem. Eur. J."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"10403","DOI":"10.1039\/C5CC03075G","article-title":"Recent development of biotin conjugation in biological imaging, sensing, and target delivery","volume":"51","author":"Ren","year":"2015","journal-title":"Chem. Commun."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"994","DOI":"10.2174\/138945012800675650","article-title":"Sodium Dependent Multivitamin Transporter (SMVT): A Potential Target for Drug Delivery","volume":"13","author":"Mitra","year":"2012","journal-title":"Curr. Drug Targets"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.tips.2017.01.003","article-title":"Cell-Penetrating Peptides: From Basic Research to Clinics","volume":"38","author":"Guidotti","year":"2017","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1080\/17425247.2019.1676720","article-title":"Cell penetrating peptides: The potent multi-cargo intracellular carriers","volume":"16","author":"Kardani","year":"2019","journal-title":"Expert Opin. Drug Deliv."},{"key":"ref_123","doi-asserted-by":"crossref","unstructured":"Neugebauer, U., Pellegrin, Y., Devocelle, M., Forster, R.J., Signac, W., Moran, N., and Keyes, T.E. (2008). Ruthenium polypyridyl peptide conjugates: Membrane permeable probes for cellular imaging. Chem. Commun., 5307\u20135309.","DOI":"10.1039\/b810403d"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"14323","DOI":"10.1039\/C5DT01833A","article-title":"Osmium(II) polypyridyl polyarginine conjugate as a probe for live cell imaging; A comparison of uptake, localization and cytotoxicity with its ruthenium(II) analogue","volume":"44","author":"Byrne","year":"2015","journal-title":"Dalt. Trans."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"6551","DOI":"10.1039\/C6SC02588A","article-title":"Precision targeted ruthenium(II) luminophores; Highly effective probes for cell imaging by stimulated emission depletion (STED) microscopy","volume":"7","author":"Byrne","year":"2016","journal-title":"Chem. Sci."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"6945","DOI":"10.1021\/jacs.8b02711","article-title":"Targeting Photoinduced DNA Destruction by Ru(II) Tetraazaphenanthrene in Live Cells by Signal Peptide","volume":"140","author":"Burke","year":"2018","journal-title":"J. Am. Chem. Soc."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"12420","DOI":"10.1002\/anie.201806002","article-title":"Highly Selective Mitochondrial Targeting by a Ruthenium(II) Peptide Conjugate: Imaging and Photoinduced Damage of Mitochondrial DNA","volume":"57","author":"Burke","year":"2018","journal-title":"Angew. Chemie Int. Ed."},{"key":"ref_128","doi-asserted-by":"crossref","unstructured":"Cullinane, D., Gkika, K.S., Byrne, A., and Keyes, T.E. (2020). Photostable NIR emitting ruthenium(II) conjugates; uptake and biological activity in live cells. J. Inorg. Biochem., 207.","DOI":"10.1016\/j.jinorgbio.2020.111032"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"40869","DOI":"10.1039\/C6RA06086B","article-title":"An efficient route to asymmetrically diconjugated tris(heteroleptic) complexes of Ru(ii)","volume":"6","author":"Burke","year":"2016","journal-title":"RSC Adv."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1039\/c2sc01127a","article-title":"A spontaneous gold(i)-azide alkyne cycloaddition reaction yields gold-peptide bioconjugates which overcome cisplatin resistance in a p53-mutant cancer cell line","volume":"3","author":"Alborzinia","year":"2012","journal-title":"Chem. Sci."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1039\/C9DT03856F","article-title":"A HCBP1 peptide conjugated ruthenium complex for targeted therapy of hepatoma","volume":"49","author":"Wang","year":"2020","journal-title":"Dalt. Trans."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1021\/jacs.6b13399","article-title":"Mitochondria Targeted Protein-Ruthenium Photosensitizer for Efficient Photodynamic Applications","volume":"139","author":"Chakrabortty","year":"2017","journal-title":"J. Am. Chem. Soc."}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/26\/11\/3153\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:07:30Z","timestamp":1760162850000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/26\/11\/3153"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,25]]},"references-count":132,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021,6]]}},"alternative-id":["molecules26113153"],"URL":"https:\/\/doi.org\/10.3390\/molecules26113153","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,25]]}}}